by Portfolio Grader | May 24, 2013 4:00 pm
The grades of five Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Alimera Sciences (NASDAQ:ALIM) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The stock price has risen 46.4% over the past month, better than the 5.1% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ALIM stock.
Johnson & Johnson (NYSE:JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The current dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb (NYSE:BMY) shows solid improvement this week. The company’s rating rises from a C to a B. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 15.2% over the past month. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Watson Pharmaceuticals’ (NYSE:WPI) ratings are looking better this week, moving up to an A from last week’s B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This is a strong week for Repros Therapeutics (NASDAQ:RPRX). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/05/5-pharmaceutical-stocks-to-buy-now-alim-jnj-bmy/
Short URL: http://invstplc.com/1nB36pT
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.